Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621295 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2896859 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1554816 | 1.00 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL31460273 | 0.93 | SMN1; SMN2 (0.76) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16903396 | 0.92 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL70761 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL70762 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2621382 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2621378 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL25145187 | 0.88 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PROMIDIS S.R.L. (IT) | 2024-04-04 | — | — | US | disclosed |
| EP-4288431-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167682-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-08-11 | — | — | WO | disclosed |
| EP-4039685-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021124279-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-06-24 | — | — | WO | disclosed |
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| EP-2970340-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10294248-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2018-09-27 | — | — | US | disclosed |
| US-9944658-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| EP-1643998-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-5753659-A | ANTICOAGULANTS FOR BLOOD DISORDER, CARDIOVASCULAR DISORDER, THROMBOSIS, | ZENECA LIMITED (GB) | 1998-05-19 | — | — | US | disclosed |
| US-5750754-A | TERTIARY BUTYL 3-METHYL-4-SUBSTITUTED BUTYRATE; CHEMICAL INTERMEDIATES FOR ANTICAOGULANT DRUGS | ZENECA LIMITED (GB) | 1998-05-12 | — | — | US | disclosed |
| US-5571909-A | ANTIBIOTICS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1996-11-05 | — | — | US | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | SMN1; SMN2 2444/4885NPC1 4491/4885RAB9A 1933/4885 |
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PTPN22, PTPN2, PTPN5 | SMN1; SMN2 4426/4885NPC1 3953/4885RAB9A 1496/4885 |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | TACR2, TAC3, TACR1 | SMN1; SMN2 4576/4885NPC1 815/4885RAB9A 2076/4885 |
| US-10294248-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | SMN1; SMN2 2444/4885NPC1 4491/4885RAB9A 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.